Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Non-Current Liabilities (2016 - 2017)

Historic Total Non-Current Liabilities for Cytosorbents (CTSO) over the last 5 years, with Q2 2017 value amounting to $13.1 million.

  • Cytosorbents' Total Non-Current Liabilities rose 8732.68% to $13.1 million in Q2 2017 from the same period last year, while for Jun 2017 it was $13.1 million, marking a year-over-year increase of 8732.68%. This contributed to the annual value of $6.5 million for FY2016, which is 36494.75% up from last year.
  • Per Cytosorbents' latest filing, its Total Non-Current Liabilities stood at $13.1 million for Q2 2017, which was up 8732.68% from $8.2 million recorded in Q1 2017.
  • Cytosorbents' 5-year Total Non-Current Liabilities high stood at $13.1 million for Q2 2017, and its period low was -$1.5 million during Q4 2014.
  • In the last 4 years, Cytosorbents' Total Non-Current Liabilities had a median value of $6.8 million in 2016 and averaged $5.5 million.
  • Examining YoY changes over the last 5 years, Cytosorbents' Total Non-Current Liabilities showed a top increase of 40259.47% in 2017 and a maximum decrease of 8732.68% in 2017.
  • Cytosorbents' Total Non-Current Liabilities (Quarter) stood at -$1.5 million in 2014, then surged by 196.59% to $1.4 million in 2015, then surged by 364.95% to $6.5 million in 2016, then skyrocketed by 100.53% to $13.1 million in 2017.
  • Its last three reported values are $13.1 million in Q2 2017, $8.2 million for Q1 2017, and $6.5 million during Q4 2016.